mrg-110
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2018 (NCT03494712)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MicroRNA 92INHIBITOR
MicroRNA 92 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mrg-110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03603431 | Phase 1 | Apr 9, 2018 | miRagen Therapeutics, Inc. |
| NCT03494712 | Phase 1 | Feb 21, 2018 | ADIR Association, Servier |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ADIR Association | Academic/Hospital | 1 | 0 | 1 | 2018 |
| miRagen Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2018 |
| Servier | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1